Purpose: Ductal carcinomas (DCs) of the lacrimal gland are very rare but aggressive malignancies. We investigated DC of the lacrimal gland for potentially clinically actionable targets in the search for new therapeutic options. Methods: Case 1: A 77-year-old man, presented with diplopia and xerophtalmia; case 2: A 53-year-old man, presented with headache, proptosis and chemosis and case 3: A 73-year-old man, presenting with chemosis and a corneal abscess. All three cases were characterized morphologically including immunohistochemistry and genetically with fluorescence in situ hybridization (FISH) and one case with next-generation sequencing (NGS) of cancer relevant genes. Results: Cases 1 and 3 were composed of large, rounded, irregular cystic nodules of carcinoma cells with prominent central comedonecrosis, whereas case 2 had a scirrhous morphology. High expression of CK7, CK19, EMA, p53 and HER2 was characteristic for all three tumours. Androgen receptor was intensely positive in case 1, in scattered cells in case 2 and negative in case 3, whereas oestrogen and progesterone receptor were consistently negative. Genetically, a hemizygous deletion and a point mutation in PTEN were identified in case 1, whereas HER2 amplification was found in cases 2 and 3. Conclusion: This study identified a spectrum of genetic events and pattern of protein expression in DC of the lacrimal gland similar to a subset of carcinomas of the breast and ductal carcinomas of the salivary glands. For therapeutic purposes, aberrations in several components of especially the HER2 signalling pathway could alleviate the effect of HER2-directed therapy illustrating an inadequacy of isolated HER2 testing.
Introduction
Ductal carcinoma (DC) is a rare but aggressive lacrimal gland malignancy with a striking histopathologic and immunohistochemical similarity to salivary duct carcinoma (SDC) of the salivary gland which resemble some types of breast carcinoma (Katz et al. 1995) . Common to these three tumour entities is the origin from the epithelial lining of the glandular ducts conveying the exocrine product of the gland to the body surface. In addition, the tumours share a frequent overexpression of the human epidermal growth factor 2 (HER2) protein and amplification of the HER2 gene (Bartlett et al. 2001; Sk alov a et al. 2001; Dennie 2015) . Anti-HER2 therapy is a well-established treatment modality in HER2-positive (HER2+) breast carcinoma, whereas variable results are found when used in HER2+ SDC in which conventional chemotherapy has proved otherwise largely inefficient (Vogel et al. 2002; Nardi et al. 2013) . To date, only one case of metastatic lacrimal gland DC has been treated with anti-HER2 treatment, resulting in stabilization of disease (Dennie 2015) . Antihormonal therapy is widely used in oestrogen receptor positive (ER+) breast carcinoma; however, neither SDC nor DC expresses ER but are instead frequently reported to be androgen receptor positive (AR+). Although ER-directed antihormonal therapy is currently used in ER+ breast carcinoma, androgen-deprivation therapy of ERÀ/AR+ breast carcinomas is gaining increased attention (Hickey et al. 2015) . Androgen-deprivation therapy has shown some effect in SDC and also in one case of metastatic DC (Jaspers et al. 2011; Ricci et al. 2014) . Despite anti-HER2 and androgen-deprivation therapy being interesting treatment strategies in the management of DC, the frequency of which HER2 protein and steroid hormone receptors is expressed in DC remains unknown.
Through recent years reports of DC cases have been accumulating, but very little is known of their genetic alteration. Recently, studies on breast carcinoma and SDC have revealed frequent mutations in several actionable cancerrelated genes, making us hypothesize that these findings could apply to lacrimal gland DC as well (Dogan et al. 2013; Chiosea et al. 2015) .
We present three cases of lacrimal gland DC and extensively characterize their immunohistochemical profile and gene copy number status with fluorescence in situ hybridization (FISH), along with mutational status in one case with suitable DNA quality with targeted next-generation sequencing (NGS) to clarify the possibilities for targeted therapy in this aggressive carcinoma.
Patients and Methods

Clinical history
Case 1
A 77-year-old man reported to our institution with 2 weeks complaints of diplopia, xerophtalmia and blepharitis on the left side. Previous medical history included bilateral cataract surgery, diabetes mellitus, aortic valve surgery and atrial fibrillation. Clinical examination of the left eye revealed ptosis (Fig. 1A) , 3-mm inferomedial displacement of the globe and restricted abduction but no proptosis. Visual acuity without correction was 0.65 on the right eye and 0.08 on the left eye and slit-lamp microscopy was unremarkable. Computerized tomography (CT) demonstrated an inhomogeneous tumour in the left lacrimal fossa with invasion of the superior rectus muscle and orbital roof (Fig. 1B) without lymph node involvement or metastatic disease, staged as T4bN0M0. The patient underwent lateral orbitotomy with removal of a 3.29292 cm tumour and the lateral orbital wall due to invasion of the bone. Radical surgery was not possible due to extensive tumour invasion of orbital bone and soft tissue. The patient received adjuvant radiotherapy (RT) (70 Gy). Computerized tomography (CT) scan at follow-up 3 months postoperatively showed no sign of residual disease. The patient died of unrelated causes 19 months after treatment.
Case 2
A 53-year-old man was admitted with complaints of lumbar pain and severe headache. Previous medical history included operation for lumbar disc prolapse and a 5-year history of increasing proptosis of the left eye. Clinical examination revealed proptosis and chemosis of the left eye. During the following 2 days of treatment, the patient went into coma and developed spastic reflexes. CT scan demonstrated dilated cerebral ventricles with multiple 
Histopathology and immunohistochemistry
Specimens from cases 1 and 3 were fixed in 10% formalin and embedded in paraffin immediately after surgical excision, whereas case 2 was removed during autopsy, all being obtained from the primary lacrimal gland lesions. Slides were stained with haematoxylin and eosin, periodic acid-Schiff (PAS) and alcian blue. , prostate-specific antigen (PSA) (clone ER-PR8, code M075029, mouse anti-human, 1:200, Dako), cyclin D1 (clone SP4-R, code 790-4508, rabbit anti-human, RTU, Roche), gross cystic disease fluid protein-15 (GCDFP-15) (23A3, code NCL-L-GCDFP15, mouse anti-human, 1:20, Novocastra (Newcastle/Tyne, UK) and p53 (DO-7, code M700101, mouse antihuman, 1:200, Dako). Positive controls as suggested on the respective datasheets were used and negative control sections omitting the primary antibody were performed. HER2 was scored according to the 2013 ASCO guidelines for breast carcinomas and AR, ER and PR scoring was performed using the Allred system (Hammond et al. 2010; Wolff et al. 2013 ).
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) was performed using the probes for FGFR1 (Zyto Vision (Dako, code K5733) and CDKN2A (Abbott Molecular, code 04N61-020) according to the manufacturers' protocol using the HYBrite platform (Abbott Molecular). After hybridization, nuclei were counterstained with DAPI II (ZytoVision). One hundred nuclei were counted, and only nuclei where the entire nuclear membrane could be visualized were scored. Amplification was defined as FGFR1/ Centromere enumeration probe (CEP) 8 > 2, HER2/CEP17 > 2.2 (12), PTEN/ CEP10 as described (Griffith et al. 2013) , MDM2/CEP12 > 2, EGFR/ CEP7 > 2 and TOP2A/CEP17>2. Loss of TOP2A and CDKN2A was defined as TOP2A/CEP17 and CDKN2A/CEP9 <0.8, respectively.
Next-generation sequencing
Deoxyribonucleic acid (DNA) was extracted from 5-lm-thick tissue sections of formalin-fixed paraffinembedded (FFPE) tumour samples by the use of the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to manufactures' instructions. Deoxyribonucleic acid (DNA) quantity was assessed using the Qubit photometer (Life Technologies, Carlsbad, CA, USA). 
Results
Histopathology
Cases 1 and 3 were composed of large, rounded, irregularly shaped cystic nodules of carcinoma cells with prominent central comedonecrosis (Fig. 1C) . Carcinoma cells with central nuclei lining the cystic nodules were arranged in a cribriform pattern with frequent "Roman bridge" formation and apocrine-like apical globules (Fig. 1D) . Small groups of carcinomatous ductal epithelial cells were found throughout a fibrous stroma between the cystic nodules. Case 2 had a scirrhous morphology dominated by dense fibrous stroma with small, solid infiltrating nests of malignant cells (Fig. 1E) . The stroma was dominated by lymphocytic infiltrates and perineural infiltration was frequent (Fig. 1E, insert) .
Histochemistry
In all three cases, PAS and Alcian blue demonstrated extracellular neutral and acidic mucin, respectively. These secretions were observed in cribriform and cystic luminae of cases 1 and 3 and in the luminae of duct-like formations in case 2.
Immunohistochemistry
High expression of CK7, CK19, EMA, p53 and HER2 was characteristic for all three tumours with only EMA, p53 and HER2 (Fig. 1F ) being expressed exclusively in the tumour cells and not in adjacent normal lacrimal gland (Table 1) . Myoepithelial markers were negative. In case 1, GCDFP-15 was intensely positive in tumour cells and necrotic material (Fig. 1G) , whereas this was only moderate in scattered tumour nests in cases 2 and 3. AR was intensely positive in case 1 (Fig. 1H) and in a few scattered cells in case 2, whereas ER and PR were consistently negative.
FISH
Case 1 had a hemizygous deletion of PTEN (38% of cells with only one signal) ( Fig. 2A) with no abnormalities of the other investigated genes, including HER2. HER2 gene amplification was found in cases 2 and 3 (HER2/ CEP17 = 5.45 and 5.4, respectively) (Fig. 2B,C) . The six remaining probes failed due to poor tissue quality in case 2 and were without abnormalities in case 3.
Next-generation sequencing
In case 1, we identified missense mutations in HRAS (c.37G>C, p.G13R) and PTEN (c.974T>G, p.L325R) and a double deletion resulting in a frameshift in CDKN2A [c.169_170del2 p.A59 fs*2 (deletion-frameshift)] (Fig. 3) with the remaining genes being wild-type. The DNA quality in cases 2 (obtained post-mortem) and 3 (35-year-old FFPE sample) was too poor for analysis.
Discussion
Our three DC patients presented with combinations of proptosis, inferonasal globe displacement, restricted eye motility and diplopia. While the symptoms in case 1 had been present for only 2 weeks, cases 2 and 3 both had 5-year histories of slowly progressive symptoms. This is markedly different from other lacrimal gland malignancies as symptoms here are typically present for less than a year before treatment (Lee et al. 1985; Eviatar & Hornblass 
Staining pattern and staining intensity: +++: diffuse positive with high intensity; ++: diffuse positive with low intensity; +: partial positive with low intensity; (+): only very few, scattered and weakly positive; À: negative. AR = androgen receptor, CEA = carcinoembryonic antigen, CK5/ 6 = cytokeratin 5/6, CK7 = cytokeratin 7, CK17 = cytokeratin 17, CK19 = cytokeratin 19, EGFR = epidermal growth factor receptor, EMA = epithelial membrane antigen, ER = oestrogen receptor, GCDFP-15 = gross cystic disease fluid protein-15, HER2 = human epidermal growth factor receptor 2, PR = progesterone receptor, PSA = prostate-specific antigen and a-SMA = a-smooth muscle actin. * Allred 7, † Allred 3, ‡ Allred 0 (Hammond et al. 2010) , § ASCO 3+ (Wolff et al. 2013 ).
1993; Heaps et al. 1993; Zeng et al. 2010 ). In our material, all patients were elderly men and according to the literature we identified a striking 4:1 male predominance with a median age of 64 years at diagnosis for de novo DCs (Table 2 ). These demographic characteristics are similar to what is found in SDC of the salivary glands, further emphasizing similarities between tumours in these organs (Gilbert et al. 2016; Andreasen et al. 2015; Andreasen et al. 2016) .
Immunohistochemically, we found complete absence of myoepithelial markers, positivity for EMA and GCDFP-15 and a cytokeratin profile dominated by CK7, 17 and 19 positivity which is in accordance with previous reports (Kurisu et al. 2005; Lee & Oh 2009; Zhu et al. 2015) . Also, cyclin D1 and EGFR were both positive and this has not previously been described in DC. All of our three cases overexpressed HER2 protein and, by reviewing the literature, we found this to be the case in 10/15 (66.6%) including previously described cases (Table 2) . While ER and PR were consistently negative, AR was intensely positive in case 1, only weak in case 2 and entirely negative in case 3. These AR-negative DCs seem to be rare, as only one AR-negative DC has previously been described while the remaining 10/12 (83.3%) were AR positive (Table 2 ). In addition to the morphologic resemblance, the immunophenotype, especially the frequent HER2 and AR expression, was strikingly similar to ductal carcinomas of the salivary glands (Brandwein-Gensler et al. 2005) . In the breast, a subset of ductal carcinoma is morphologically similar to DC and SDC and is HER2+, but is frequently ER+ rather than AR+. However, recent focus on AR and HER2 coexpression in a particular subset of aggressive breast carcinomas strengthens the connection between these three tumour entities (LehmannChe et al. 2013; Hickey et al. 2015) .
For the clinical management of lacrimal gland tumours most studies have focused on the most frequent tumour in this location, adenoid cystic carcinoma (ACC). Local control is achieved by surgery usually followed by RT, in particular in cases with perineural invasion (Fig. 1E, insert) , and new radiation delivery techniques decrease ocular toxicity (Woo et al. 2016) .
Intra-arterial cytotoxic chemotherapy as neoadjuvant treatment in lacrimal gland ACC is a promising treatment strategy, but the current standard use of cytotoxic chemotherapy is in adjuvant treatment, and in the metastatic setting (von Holstein et al. 2013; Woo et al. 2016) . Case 2 in our material presented with metastases which seems to be a somewhat rare event as only 1/17 (5.9%) cases previously reported had metastatic disease at presentation (Table 2) . However, 8/16 (50%) presenting with M0 disease and available follow-up developed distant metastases and 9/22 (40.9%) died of their disease illustrating the aggressive nature of lacrimal gland DC. This illustrates the need for implementation of novel therapeutic options which is nonetheless complicated by their rarity. Therefore, findings from look-alike tumours in other locations are interesting venues to search for candidate therapeutic targets applicable to DC. We identified HER2 gene amplification in two of our cases and not previously described aberrations in the PTEN, CDKN2A and HRAS genes in the case undergoing NGS, of which similar findings have been made in SDC and breast carcinoma (Cerilli et al. 1999; Sk alov a et al. 2001; Dogan et al. 2013; Griffith et al. 2013; Chiosea et al. 2015) . Although the oncogenic properties of HRAS and CDKN2A are well characterized, the clinical significance is currently limited as early-phase clinical trials with targeted therapies are still actively enrolling patients (clinicaltrials.gov identifier:
NCT00687622; NCT0 2513394; NCT02448420). Including the three cases presented, 10/15 (66.7%) reported cases were HER2+ by either immunohistochemistry or FISH, analogous to the proportions in breast carcinomas and SDC (Lehmann-Che et al. 2013; Limaye et al. 2013) . While appealing to employ HER2 blockage with the monoclonal antibody trastuzumab in the treatment of HER2+ DC, lessons learned from other cancers have shown that alterations in several downstream effectors are able to alleviate the effect of this treatment. Loss of the tumour suppressor gene PTEN confers this resistance in breast cancer as PTEN function is crucial in reverting the effects of constitutively active HER2 on the PI3K-AKT signalling pathway (Berns et al. 2007) . In case 1, in addition to HER2 overexpression, we found hemizygous deletion as well as a missense mutation in PTEN, suggesting that anti-HER2 therapy would have no effect in this patient despite of it being HER2 positive. Interestingly, increased frequency of PTEN deletion and decreased PTEN expression have been detected in HER2-amplified SDC, suggestive of two separate mechanisms of PI3K activation that might be the case in lacrimal gland DC as well (i.e. HER2-mediated PI3K activation and decreased PTEN-mediated PI3K inhibition) (Ettl et al. 2012) . Also, it is of special interest that HRAS is downstream of HER2, possibly undermining the effect of anti-HER2 treatment in cases with constitutively active HRAS. Despite the highlighted pitfalls in employing HER2-directed therapy, its potential benefit for this patient group is illustrated by the stabilization of metastatic disease in a patient with HER2-amplified lacrimal gland DC (Dennie 2015) . Scheduled adjuvant anti-HER2 treatment in a case of DC arising in a lacrimal gland pleomorphic adenoma has also been reported, and the outcome of this and other patients will help to establish the value of HER2 blockage in this patient group (Giliberti et al. 2011; Woo et al. 2016) . The majority of breast carcinomas are GCDFP-15+, especially the ER-/ PR-/AR+/EGFR+ apocrine carcinomas which resemble SDC in this regard (Ellis et al. 2012; Tsutsumi 2012; LehmannChe et al. 2013; Safarpour et al. 2014 ). Interestingly, case 1 showed a striking apocrine morphology and was ER-/ PR-/AR+/GCDFP-15+/EGFR+ of which mainly ER-/PR-/EGFR+ was shared with cases 2 and 3 which had comparatively few apocrine features. Androgen-deprivation therapy is currently emerging in the management of AR+ breast carcinomas, and has shown clinical response in SDC with a clinical trial currently enrolling patients (clinicaltrials.gov identifier: NCT01969578) (Jaspers et al. 2011; Gucalp et al. 2013; Nardi et al. 2013; Hickey et al. 2015) . Lending further support to the role of androgen-deprivation therapy in managing DC is the favourable response in one patient with skeletal metastases from an AR+ DC (Ricci et al. 2014 ).
In conclusion, we present the first insight into the genetics of lacrimal gland DC. The immunohistochemical profile and mutational pattern of DC strongly resemble SDC and a subset of breast carcinomas, and advances in treatment of these far more frequent malignancies could result in acceleration of available treatments in patients with lacrimal gland DC. Importantly, identification of genetic events (PTEN loss and HRAS mutations) possibly alleviating the effect of anti-HER2 treatment calls for more thorough molecular characterization than isolated HER2 testing.
